Fast Market Research

New Market Research Report: Global Lupus Therapeutic Market 2017-2021

Fast Market Research announces the availability of the new TechNavio report, "Global Lupus Therapeutic Market 2017-2021", on their comprehensive research portal


Boston, MA -- (SBWIRE) -- 06/23/2017 -- Lupus is a chronic autoimmune disease in which the body's immune system becomes hyperactive and attacks normal, healthy tissue. This results in symptoms such as inflammation, swelling, and damage to joints, skin, kidneys, blood, the heart, and lungs. Systemic lupus erythematosus (SLE) is a major disease, which is followed by lupus nephritis at the later stages. Only one drug is approved specifically for the treatment of lupus disorders and the majority of other drugs are off-label based on symptoms. Due to a strong pipeline, the market is expected for more approved drugs for lupus disorders in future.

Technavio's analysts forecast the global lupus therapeutic market to grow at a CAGR of 9.74% during the period 2017-2021.

Get More Details on this Report and a Full Table of Contents at Global Lupus Therapeutic Market 2017-2021

Covered in this report

The report covers the present scenario and the growth prospects of the global lupus therapeutic market for 2017-2021. To calculate the market size, the report considers both generic and branded drug market.

The market is divided into the following segments based on geography:


Technavio's report, Global Lupus Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

-F.Hoffmann-La Roche

Other prominent vendors

-ADMA Biologics
-Anthera Pharmaceuticals
-Bayer HealthCare
-Bristol-Myers Squibb
-Kedrion Biopharma
-LFB Group
-Takeda Pharmaceuticals

Market driver

-High prevalence rate
-For a full, detailed list, view our report

Market challenge

-Complexity of disease
-For a full, detailed list, view our report

Market trend

-Regenerative therapeutic technologies
-For a full, detailed list, view our report

Key questions answered in this report

-What will the market size be in 2021 and what will the growth rate be?
-What are the key market trends?
-What is driving this market?
-What are the challenges to market growth?
-Who are the key vendors in this market space?
-What are the market opportunities and threats faced by the key vendors?
-What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: F.Hoffmann-La Roche, GlaxoSmithKline, Medlmmune, Pfizer, ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer HealthCare, Biogen, Biotest, Bristol-Myers Squibb, Celgene, Immunomedics, Kedrion Biopharma, LFB Group, Merck, Novartis, Shire, Takeda Pharmaceuticals, UCB

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:
-PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025
-Global Diabetic Therapeutic Market 2017-2021
-Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016
-Lupus Erythematosus Global Clinical Trials Review, H2, 2016
-Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19